期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

冠心病患者MHC2TA-168A→G多态性与高敏C反应蛋白水平的相关性 被引量：1

下载PDF
导出
摘要 目的探讨冠状动脉粥样硬化性心脏病(CAD)患者Ⅱ类主要组织相容性复合物转录激活子(MHC2TA)5'启动区-168A→G多态性与血清高敏C-反应蛋白(hs-CRP)水平的关系。方法对185例CAD患者采用错配聚合酶链反应-限制性片段长度多态性技术(mpPCR-RFLP)检测MHC2TA基因-168A→G多态性并免疫比浊法测定hs-CRP水平,分析两者之间的关系。结果 185例CAD患者MHC2TA基因-168A→G多态性:呈AA基因型95例(51.35%)、AG基因型78例(42.16%)、GG基因型12例(6.49%);hs-CRP水平:GG基因型患者hs-CRP(4.5±1.8)mg/L及AG基因型患者(3.2±1.2)mg/L与AA基因型患者(2.7±1.1)mg/L比较差异有统计学意义(t=11.06、9.14,均P<0.05);hs-CRP>3.0 mg/L的高危患者GG基因型占(91.7%)及AG基因型(73.4%)与AA基因型高危患者(45.2%)比较,差异有统计学意义(χ2=17.75,28.04,均P<0.05)。结论MHC2TA-168A→G多态性G等位可能是CAD炎症反应的独立影响因素,MHC2TA-168A→G多态性可能与CAD炎症反应有关。
作者 段成城 陈倩
机构地区 广州医学院附属深圳沙井医院心内科 广州医学院附属深圳沙井医院产科
出处 《中国老年学杂志》 CAS CSCD 北大核心 2013年第14期3315-3317,共3页 Chinese Journal of Gerontology
关键词 冠状动脉粥样硬化性心脏病 Ⅱ类主要组织相容性复合物转录激活子 基因多态性 HS-CRP
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献15

  • 1Hansson GK. Inflammation,atherosclerosis,and coronary artery disease[J]. N Engl Med,2005;352(16) : 1685-95.
  • 2Mallat Z,Gojova A,Brun Y,et al. Induction of a regulatory T cell type 1response reduces the development of atherosclerosis in apolipoprotein E-knockout mice[J]. Circulation, 2003 ; 108 ( 10) : 1232-7.
  • 3SwanbergM, Lidman 0, Padyukov L,et al. MHC2TA is associated withdifferential MHC molecule expression and susceptibility to rheumatoid ar-thritis ,multiple sclerosis and myocardial infarction [ J ]. Nat Genet, 2005 ;37(5) :486-94.
  • 4NagarajanUM,Bushey A,Boss JM. Modulation of gene expression by theMHC class II transactivator[ J]. Immunology ,2002 ; 169(9) :5078-88.
  • 5Ting JP,Trowsdale J. Genetic control of MHC class H expression[ J].Cell,2002;109(suppl) :21-33.
  • 6LindholmE, Melander 0,Almgren P, et al. Polymorphism in theMHC2TA gene is associated with features of the metabolic syndrome andcardiovascular mortality[J]. PLoS ONE,2006;20( 1) :e64.
  • 7FluiigelA, Berkowicz T, Ritter T,ef al. Migratory activity and functionalchanges of green fluorescent effector cells before and during experimentalautoimmune encephalomyelitis[J]. Immunity,2001 ;14(5) :547-60.
  • 8Kwak B,Mulhaupt F,Myit S,et al. Statins as a newly recognized type ofimmunomodulator[ J]. Nat Med,2004;6( 12) :1399402.
  • 9Nozellt S,Ma ZD,Wilson C,et al. Benveniste Class II Major Histocom-patibility Complex Transactivator (CD TA) inhibits matrix metalloprotein-ase-9 gene expression[ J]. J Biol Chem,2004 ;279(37) :38577-89.
  • 10Ridker PM. Clinical application of C-reactive protein for cardiovasculardisease detection and prevention[ J]. Circulation,2003 ; 107(3) :363.'.

二级参考文献21

  • 1Zee R, Ridker PM. Polymorphism in the bnman C-reactive protein (CRP) gene, plasma concentrations of CRP, end the risk of future arterial thrombosis. Atherosclemsis, 2002, 162:217-219.
  • 2Cao H, Hegele RA. Human C-reactive protein (CLIP) 1059G/C polymorphism. J Hum Genet, 2000, 55:100-101.
  • 3Ferranti SD, Rifai N. C-reactive protein end cardiovascular disease: a review of risk prediction end intervention. Clin Chim Acta. 2002, 317 : 1-15.
  • 4Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and longterm mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation, 2002,105 : 1412-1415.
  • 5Ridker PM, Rifai N, Pfeffer M.A, et al. Long-term effects of provastatin on plasma concentration of C-reactive protein. Cholesterol and Recurrent Events (CARE) Investi~tars. Circulation, 1999,100:230-235.
  • 6Vickers MA, Green FR, Terry C, et al. Genotype at a promoter polymorphism of the intedeukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res, 2002, 53:1029-1034.
  • 7Hoffemeister HM, Elders R, Buttcher E, et al. Comparison of Creactive protein and terminal complement complex in patients with unstable angina pectoris versus stable .angina pectoris. Am J Cardiol, 2002, 89:909-912.
  • 8Haidari M, Javadi E, Sadeghi B, et al. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin Biochem, 2001, 33:309-315.
  • 9Koenig W, Sund M, Fmhlich M, et al. C-reactlve protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Detennimmts in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circuhtion, 1999,99:237-242.
  • 10Bidker PM, Hennekens CH, Buring JE, et al. C-reactive protein, and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl. J Med, 2000, 342:836-843.

共引文献85

同被引文献11

引证文献1

二级引证文献1

中国老年学杂志
2013年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部